83397-45-9

Upstream product

• 7664-93-9 sulfuric acid 
• 71825-51-9 4-(2-cyanoprop-2-yl)-1-nitrobenzene 
• 5445-26-1 ETHYL 4-NITROPHENYLACETATE 
• 74-88-4 methyl iodide 
• 98-95-3 nitrobenzene 
• 535-13-7 2-chloro-propanoic acid, ethyl ester 
• 1195-98-8 2-methyl-2-phenylpropionitrile 
• 2901-13-5 ethyl 2-methyl-2-phenylpropionate 
• 7646-69-7 sodium hydride 
• 50712-64-6 ethyl 2-(4-nitrophenyl)propionate 
• 865-48-5 sodium t-butanolate 

Downstream Products

• 36924-81-9 ethyl 2-(4-aminophenyl)-2-methylpropanoate 
• 42206-47-3 2-methyl-2-(4-nitro-phenyl)-propionic acid 
• 18755-53-8 2-methyl-2-(4-nitrophenyl)propan-1-ol 
• 1076219-11-8 ethyl 2-[2-(3,5-dimethylphenyl)-1H-indol-5-yl]-2-methylpropanoate 
• 1076219-12-9 ethyl 2-methyl-2-{2-[4-(trifluoromethoxy)phenyl]-1H-indol-5-yl}propanoate 
• 1076220-87-5 2-[2-(3,5-dimethylphenyl)-1H-indol-5-yl]-2-methylpropanoic acid 
• 1076219-29-8 2-[2-(3,5-dimethylphenyl)-1H-indol-5-yl]-(N-cyclopropyl)-2-methylpropanamide 
• 192643-90-6 ethyl 2-(4-hydrazinophenyl)-2-methylpropanoate 
• 18755-56-1 2-(4-aminophenyl)-2-methylpropan-1-ol 
• 357193-21-6 tert-butyl 5-[2-(7-azabicyclo[2.2.1]hept-7-yl)-1,1-dimethyl-2-oxoethyl]-3-[(1S)-2-{[(2,4-dinitrophenyl)sulfonyl]amino}-1-methylethyl]-2-(3,4,5-trimethylphenyl)-1H-indole-1-carboxylate 
• 357193-23-8 tert-butyl 5-[2-(7-azabicyclo[2.2.1]hept-7-yl)-1,1-dimethyl-2-oxoethyl]-3-[(1S)-1-methyl-2-[(2-pyridin-4-ylethyl)amino]ethyl]-2-(3,4,5-trimethylphenyl)-1H-indole-1-carboxylate 
• 357193-15-8 tert-butyl 5-[2-(7-azabicyclo[2.2.1]hept-7-yl)-1,1-dimethyl-2-oxoethyl]-3-[(1S)-2-(benzyloxy)-1-methylethyl]-2-(3,4,5-trimethylphenyl)-1H-indole-1-carboxylate 
• 357193-17-0 tert-butyl 5-[2-(7-azabicyclo[2.2.1]hept-7-yl)-1,1-dimethyl-2-oxoethyl]-3-[(1S)-2-azido-1-methylethyl]-2-(3,4,5-trimethylphenyl)-1H-indole-1-carboxylate 
• 357193-19-2 tert-butyl 5-[2-(7-azabicyclo[2.2.1]hept-7-yl)-1,1-dimethyl-2-oxoethyl]-3-[(1S)-2-amino-1-methylethyl]-2-(3,4,5-trimethylphenyl)-1H-indole-1-carboxylate 

Relevant academic research and scientific papers

Immunomodulator

The invention discloses an immunomodulator, and particularly relates to a compound shown as a formula I, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. Experiments prove that the compound has good IL-17A inhibitory activity, can be used for preparing an IL-17A inhibitor and drugs for preventing and/or treating IL-17A mediated diseases (such as inflammation, autoimmune diseases, infectious diseases, cancers and precancerous syndromes), and provides a new medical possibility for clinical treatment of diseases related to abnormal IL-17A activity.

Immunomodulator

The invention discloses an immunomodulator, and particularly relates to a compound for inhibiting IL-17A and application of the compound serving as the immunomodulator in preparation of drugs. The invention discloses application of a compound shown in a formula I or a stereoisomer thereof in preparation of medicines for inhibiting IL-17A, and provides a new choice for clinically screening and/or preparing medicines for treating diseases related to IL-17A activity.

COMPOUNDS AND METHODS FOR INHIBITING CYP26 ENZYMES

Compounds described herein are inhibitors of retinoic acid inducible P450 (CYP26) enzymes, and are useful for treating diseases that are responsive to retinoids. Certain compounds have retinoid activity, are resistant to CYP26-mediated catabolism, and are used for treating diseases that are responsive to retinoids.

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

2,4-Pyrimidinediamine Compounds and Their Uses

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS

Compounds of formula (Ι') that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

QUINAZOLINE DERIVATIVES

Novel quinazolinamide derivatives of the formula (I), in which R1-R4 and X have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.